107例子宫腺肌瘤局灶切除术的临床疗效分析

目的：探讨子宫腺肌瘤局灶切除术的可行性及安全性。方法：回顾分析2005年10月-2012年3月南京医科大学附属苏州医院收治的有症状的107例子宫腺肌瘤患者治疗资料,所有患者均坚决要求保留子宫,均行子宫腺肌瘤局灶切除术,其中100例行经腹小切口子宫腺肌瘤局灶切除术,7例行腹腔镜下子宫腺肌瘤局灶切除术。比较分析患者手术时间、术中出血量、术后痛经及月经量的改善情况及子宫腺肌瘤复发情况。结果：术后6个月的随访中,接受随访的79例患者痛经症状均完全消失,43例月经过多患者月经量均恢复正常。术后48个月接受随访的28例患者中,有2例（7.1%）患者部分缓解,均予口服止痛药治疗;术后60个月接受随访的14例患者中,2例（14.3%）患者部分缓解,1例予口服止痛药治疗,1例予左炔诺孕酮宫内缓释系统（LUG-IUS,商品名曼月乐）治疗;2例（14.3%）患者痛经程度与术前级别相同,术后60个月行全子宫切除术。7例不孕患者中有1例术后3年妊娠,足月分娩;3例已育患者分别于术后2个月～1年妊娠,均行药物流产,另3例不孕患者术后至今未孕。结论：大多数有症状的子宫腺肌瘤患者可通过子宫腺肌瘤局灶切除术,达到完全缓解痛经及月经量过多的症状,疗效确切,可以成为替代全子宫切除术的成功手术方式,值得临床推广应用。     

子宫腺肌病腹腔镜病灶切除术后应用促性腺激素释放激素激动剂联合中药内异消临床研究

目的探讨腹腔镜病灶切除术后应用促性腺激素释放激素激动剂(GnRH-a)联合中药内异消治疗子宫腺肌病并保留生育功能的可行性。方法收集2014年10月至2016年10月在上海中医药大学附属曙光医院妇科住院治疗的生育期子宫腺肌病患者32例,应用悬吊式腹腔镜联合改良环形电切术进行子宫腺肌病病灶切除术,术后均给予注射Gn RH-a治疗6个月及中药内异消口服12个月。术后随访18个月,比较治疗前后月经量、痛经、子宫体积、血清CA125变化情况和中医证候积分以及复发率和妊娠率。结果与治疗前比较,Gn RH-a治疗后首次月经来潮时及术后12、18个月的月经量、痛经和中医证候积分差异有统计学意义(P0.05),子宫体积和血清CA125均显著下降(P0.05)。手术后18个月复发率3.13%,妊娠率6.25%。内异消服用12个月后,患者肝肾功能均正常。结论子宫腺肌病腹腔镜病灶切除术后应用GnRH-a联合中药内异消治疗可显著改善月经过多、痛经等症状,复发率降低,部分患者仍可妊娠分娩。内异消长期服用无明显影响肝肾功能等副反应。     

腹腔镜下子宫腺肌病病灶切除术联合促性腺激素释放激素激动剂治疗子宫腺肌病的疗效观察

目的:探讨腹腔镜下子宫腺肌病病灶切除术联合促性腺激素释放激素激动剂(GnRH-a)治疗子宫腺肌病的临床疗效及安全性。方法:对59例子宫腺肌病患者行腹腔镜下子宫腺肌病病灶切除术治疗,其中术后自愿接受GnRH-a治疗的38例患者为实验组,未接受GnRH-a治疗的21例患者为对照组。首次用药(术后第1个月)后1、3、6、12个月监测子宫体积、痛经程度、月经量、血清CA125水平、血红蛋白(Hb)量及副反应的发生。结果:对照组随访至12个月时,痛经改善情况较随访第1个月时显著减弱(χ2=4.50,P=0.034),但与术前痛经情况比较仍有显著改善(χ2=4.20,P=0.040)。实验组和对照组的子宫体积在随访6、12个月时差异有统计学意义(P0.05),经量过多及痛经改善情况在随访12个月时出现显著性差异(χ12=4.89,P1=0.027;χ2=8.76,P=0.033),而CA125水平在随访3个月时已出现显著性差异(P0.05);两组的贫血改善情况比较,差异无统计学意义(P0.05)。治疗过程中,实验组需反向添加治疗患者共17例,添加治疗后,E2水平均维持在110~165pmol/L,潮热出汗、骨关节痛等围绝经期症状均得到不同程度的改善。结论:腹腔镜下子宫腺肌病病灶切除术可有效缓解患者的症状,术后联合GnRH-a治疗后可获得更满意的近期效果,且用药后出现的围绝经期症状经反向添加治疗后均可得到不同程度的改善,值得临床推广。     

腹腔镜保守手术治疗子宫腺肌瘤疗效观察

目的探讨子宫腺肌瘤腹腔镜保守手术的临床特点和治疗效果。方法以2004年4月到2007年7月于北京协和医院行腹腔镜子宫腺肌瘤病灶挖除术的72例患者为研究对象,记录其临床特点、辅助治疗、随访结果和妊娠结局,回顾性分析复发和妊娠的相关因素。结果 (1)腹腔镜子宫腺肌瘤病灶挖除术后2年,患者痛经程度减轻,子宫体积缩小,血清CA125值下降,和术前相比差异有统计学意义(P<0.05)。(2)术后症状复发率34.7%,复发中位时间30个月。复发组患者的年龄和子宫体积更大,术后妊娠者的复发率低于未妊娠者(P<0.05)。(3)和单纯手术组相比,术后辅助促性腺激素释放激素激动剂(GnRHa)组患者的子宫体积更大、多发腺肌瘤及合并子宫内膜异位症的比例更高(P<0.05),但两组复发率差异无统计学意义。(4)术后妊娠率68.8%,分娩率46.9%。妊娠距离手术的中位时间为13个月。未发现影响妊娠的有统计学意义的临床因素。结论对于有生育要求的局限性腺肌瘤患者,腹腔镜子宫腺肌瘤病灶挖除术能有效缓解症状、促进妊娠。年轻、子宫体积大的患者更容易复发,术后妊娠对复发有保护作用。术后联合GnRHa治疗有助于减少复发,但对妊娠的益处尚不肯定。     

腹腔镜病灶切除术联合戈舍瑞林治疗子宫腺肌瘤30例

目的:观察腹腔镜病灶切除术联合戈舍瑞林治疗子宫腺肌瘤的临床疗效.方法:选取30例子宫腺肌瘤患者行腹腔镜病灶切除术,术后予戈舍瑞林治疗3个月.结果:30例患者手术及戈舍瑞林治疗后痛经缓解率为100%;月经量较术前明显减少(P<0.01);月经周期和经期无明显改变(P>0.05);有8例患者药物副反应表现为低雌激素水平症状如潮热、多汗、阴道干燥、性欲下降等,全部患者肝功能无明显变化;1例患者复发.结论:腹腔镜病灶切除术联合戈舍瑞林治疗子宫腺肌瘤能有效缓解痛经、经血过多等症状,保留了患者的生育器官,是一种有效、微创、安全的治疗方法.     

腹腔镜子宫腺肌瘤切除联合子宫动脉阻断术对内膜白血病抑制因子的影响

目的探讨腹腔镜子宫腺肌瘤切除术联合子宫动脉阻断对子宫内膜容受性的影响及意义。方法选取2014年6月—2015年6月期间就诊福建省立医院妇科的子宫腺肌病(伴子宫腺肌瘤)患者共42例,随机分对照组(n=21)和观察组(n=21),对照组行腹腔镜下子宫腺肌瘤剔除术,观察组行腹腔镜子宫腺肌瘤剔除联合子宫动脉阻断术。所有患者术后均注射长效促性腺激素释放激素类似物(Gn RHa)6个月。比较两组患者平均年龄、最大腺肌瘤、子宫最大径线和CA125水平及患者术前、及术后12个月、24个月子宫内膜容受性标志物——白血病抑制因子(LIF)m RNA水平。结果患者年龄、最大腺肌瘤径线、子宫最大径线及CA125水平组间比较差异均无统计学意义。两组患者术前LIF m RNA(0.73±0.17、0.70±0.18)及术后12个月LIF m RNA(0.98±0.22、0.99±0.22)分别比较差异无统计学意义(P0.05);术后24个月内膜LIF m RNA观察组(1.02±0.21)明显高于对照组(0.86±0.22)(P=0.022)。结论子宫腺肌瘤病灶切除术联合Gn RHa治疗可改善LIF m RNA的转录;联合子宫动脉阻断术可有助于子宫腺肌瘤病灶切除术的效用,有助于改善子宫内膜容受性。     

腹腔镜下多术式联合治疗子宫腺肌病的临床观察

目的:探讨腹腔镜下子宫动脉阻断术(UAB)、子宫腺肌病病灶切除术、子宫神经去除术(LUNA))联合应用治疗子宫腺肌病(AM)的临床效果。方法:80例AM患者随机分为观察组38例行UAB+病灶切除术+LUNA,对照组42例行腹腔镜子宫腺肌病病灶切除术,观察两组围手术期情况及术后月经量、子宫体积、痛经评分及血清CA125水平变化。结果:①观察组手术时间(76.5±11.7分钟)长于对照组(52.3±12.8分钟),差异有统计学意义(P0.05);对照组术后血红蛋白下降较观察组明显(P0.05)。②观察组和对照组,术后月经量、痛经评分、子宫体积、血CA125均较术前明显下降(P0.05),术后12个月起两组间痛经评分、子宫体积、CA125同期比较,差异有统计学意义(P0.05),术后36个月两组痛经缓解率(90.9%vs69.4%)、复发率(9.1%vs 30.6%)比较,差异有统计学意义(P0.05)。结论:UAB、病灶切除术、LUNA联合治疗AM近期安全有效,可提高痛经缓解率,延缓复发。     

宫腔镜病灶切除术联合宫腔内左炔诺孕酮释放系统治疗内突型子宫腺肌瘤的近中期临床疗效观察

目的探讨宫腔镜下病灶切除术联合宫腔内左炔诺孕酮释放系统(LNG-IUS)治疗内突型子宫腺肌瘤的近中期临床疗效。方法对2014-01-01—2015-04-31期间大连医科大学附属大连市妇幼保健院18例子宫腺肌瘤患者行宫腔镜下病灶切除术联合LNG-IUS治疗,记录手术时间、术中及术后并发症情况,比较术前及术后的痛经改善情况、月经量的变化、子宫体积的变化及子宫腺肌瘤复发情况。结果 18例宫腔镜下子宫腺肌瘤病灶切除术手术时间(58.3±6.4)min,无术中、术后并发症。术后随访6~12个月。14例痛经患者,2例(2/14,14.3%)部分缓解,5例(5/14,35.7%)明显缓解,5例(5/14,35.7%)完全缓解,2例(2/14,14.3%)无月经来潮。14例经量多者,术后经量均减少、经期缩短,且差异有统计学意义[为术前的(29.3±0.7)%,P0.05];月经周期术前术后差异无统计学意义[(7.8±3.3)d vs.(4.3±2.2)d,P0.05]。10例合并不同程度贫血者贫血均纠正。术后6个月子宫体积均缩小,且差异有统计学意义[(232.5±94.5)cm3vs.(123.8±59.4)cm3,P0.05],随访期间彩超均未提示子宫腺肌瘤复发。8例(8/18)术后阴道分泌物量多、稀薄;4例(4/18)术后3个月内有点滴阴道流血,均于3~6个月渐恢复正常;1例(1/18)体重增加。2例(2/18)因阴道分泌物较多表示满意度欠佳,余均满意。结论宫腔镜下子宫腺肌瘤病灶切除术联合LNG-IUS治疗内突型子宫腺肌瘤近中期疗效明显。     

卵巢子宫内膜异位囊肿合并不孕患者术后治疗探讨

目的:探讨卵巢子宫内膜异位囊肿合并不孕的患者术后治疗策略。方法:将腹腔镜下卵巢子宫内膜异位囊肿剥除术后要求妊娠的62例不孕患者随机分为期待组(n=31)和GnRH-a组(n=31)。期待组腹腔镜手术后随访观察,避免使用激素类药物;GnRH-a组腹腔镜手术后月经第1日给予GnRH-a治疗:达菲林3.75 mg皮下注射,1次/28 d,连用3次停药。所有患者随访24个月,观察24个月内妊娠情况。结果:期待组12个月内妊娠率为41.9%(13/31),13~24个月内妊娠率为22.2%(4/31),24个月累积妊娠率为54.8%(17/31)。GnRH-a组1年内妊娠率为48.4%(15/31),13~24个月内妊娠率为18.8%(3/31),24个月累积妊娠率为58.1%(18/31)。期待组与GnRH-a组比较,12个月内妊娠率、24个月累积妊娠率组间均无统计学差异(P0.05)。结论:初步临床观察,卵巢子宫内膜异位囊肿剥除术后使用GnRH-a在提高EMs合并不孕患者妊娠率方面未显示出优势。     

腹腔镜下子宫肌瘤剥除术中先行子宫动脉阻断可行性研究

目的:探讨腹腔镜下子宫动脉阻断后行肌瘤剥除治疗子宫肌瘤的临床效果及可行性.方法:根据不同方法对120例要求保留子宫的子宫肌瘤患者随机分为两组.研究组60例,采用腹腔镜下双侧子宫动脉阻断后行肌瘤剥除术;对照组60例,采用腹腔镜下常规子宫肌瘤剥除术.肌瘤数目、大小、发病年龄两组间差异无统计学意义.统计手术时间、术中出血量,术后定期随访观察月经症状的改变,B超检查监测子宫大小及肌瘤复发情况,并将两组进行对照比较.结果:研究组平均手术时间(92.5±31.2)分钟,与对照组(103.8±48.6)分钟相近(P＞0.05);研究组术中出血量(87.5±48.4)ml,明显少于对照组(233.0±86.0)ml(P＜0.05);两组随访均在2年以上,平均随访26个月,研究组失访9例,对照组失访8例;研究组术后2年所有患者E2值均在正常范围;术后2年,研究组和对照组94.1%和78.8%的患者子宫恢复到正常大小,两组比较差异有统计学意义;研究组月经症状缓解率93.6%,明显高于对照组79.1%(P＜0.05);肌瘤复发率3.9%,明显低于对照组23.1%(P＜0.05).结论:腹腔镜下子宫动脉阻断后行肌瘤剥除治疗子宫肌瘤与常规腹腔镜下肌瘤剥除术相比,能明显减少术中出血,更好地缓解月经过多等症状,延缓了肌瘤的复发,具有更好的临床应用价值.     

不同黄体生成素与卵泡刺激素比值的多囊卵巢综合征患者抗苗勒管激素分泌特点及卵泡发育障碍机制

目的 比较不同血清黄体生成素(LH)与卵泡刺激素(FSH)比值(LH/FSH)的多囊卵巢综合征(PCOS)患者的抗苗勒管激素(AMH)分泌特点及卵泡发育障碍机制.方法 以LH/FSH为标准,将95例PCOS患者分为高比值组(49例,LH/FSH≥2),常比值组(46例,LH/FSH<2),以62例月经周期规则的输卵管性不孕患者为对照(对照组).3组患者均测定体质指数(BMI);采用酶联免疫吸附试验(ELISA)测定血清AMH水平;采用化学发光法测定血清生殖激素、空腹血糖、胰岛素及血脂水平;采用单因素方差分析法比较各组间生化代谢指标的差异;并运用简单相关分析法和多重线性回归法分析AMH水平与各生化代谢指标的关系.结果 (1)血清AMH水平:高比值组为(7.2±4.3)μg/L,常比值组为(5.2±3.8)μg/L,对照组为(3.7±2.2)μg/L,3组分别比较,差异均有统计学意义(P<0.01).(2)血清AMH水平与生化代谢指标的相关性:高比值组患者血清AMH水平与雌二醇水平呈负相关关系(r=-0.318);常比值组患者血清AMH水平与BMI、空腹血糖、稳态模型胰岛索抵抗指数(HOMA-IR)呈正相关关系(r=0.493、0.362、0.303).控制其他因素影响后,高比值组患者血清AMH水平与LH/FSH呈正相关关系(r=0.301),与雌二醇水平呈负相关关系(r=-0.429);常比值组患者血清AMH水平与BMI呈正相关关系(r=0.493).结论 高LH/FSH的PCOS患者卵泡发育障碍机制可能以下丘脑-垂体功能障碍为主,正常LH/FSH的PCOS患者则以代谢紊乱为主.     

Recombinant luteinizing hormone priming in multiple follicular stimulation for in-vitro fertilization in downregulated patients

Follicle development is controlled amongst other factors by pituitary gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) that act in synergy in completing follicle maturation. Exogenous gonadotropins, combined with gonadotropin-releasing hormone agonists, have been successfully used in patients with ovulatory disorders undergoing assisted reproduction. There is some evidence of a beneficial role of androgens or LH administration before FSH stimulation. This study was designed to verify whether the addition of LH in the early follicular phase, in downregulated patients undergoing follicular stimulation for assisted reproduction, would add benefits in terms of general outcomes and pregnancy rates. We compared two groups of patients one of which was treated with recombinant FSH (rFSH) alone and the other with rFSH plus recombinant LH (rLH), in the early follicular phase only. The number of eggs recovered was higher in the group treated with FSH only; however, the number of embryos available at transfer was similar in the two groups and, more importantly, the number of Grades I and II embryos was higher in the group pretreated with LH. Similarly, although biochemical pregnancy rate and clinical pregnancy rates were similar in both groups, a beneficial role of LH priming was demonstrated by the higher implantation rate achieved in these patients.     

Phase II study of cetrorelix,a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

OBJECTIVE: The goal of this work was to study the anticancer activity of cetrorelix, a decapeptide with LHRH receptor antagonist properties in patients with platinum-resistant ovarian cancer. About 80% of primary ovarian cancers and cell lines bear LHRH receptors. Cetrorelix has anticancer activity in in vitro and in vivo ovarian cancer models. METHODS: Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day. Eligibility criteria included age > or = 18, PS < or = 2, measurable disease, chemistries and blood counts in normal range, no estrogen replacement for at least 2 weeks, and no known allergic reactions to extrinsic peptide. In patients volunteering for a biopsy, tissue was taken to perform a LHRH receptor assay. RESULTS: Seventeen patients were treated. Median age was 58 years. Median performance status was 0. Median number of prior chemotherapies was 3. Three patients had partial remissions lasting 9, 16, and 17 weeks. Toxicities effects included grade 4 anaphylactoid reaction (one patient) controlled by cortisol and cimetidine, grade 2 histamine reaction (two patients), grade 2 arthralgia (one patient) 20% cholesterol increase (two patients, who did not require specific treatment), minor hot flushes, headache, and local skin reaction at the injection site. Six of seven samples were LHRH receptor positive for mRNA and/or ligand assay. Two responding patients were LHRH receptor positive. The patient who had no receptor did not respond. CONCLUSION: Cetrorelix has activity against ovarian cancer in this refractory population, and has minimal toxicity, except for potential anaphylactoid reactions. Activity may be mediated through the LHRH receptor.     

Anti-Mullerian Hormone: A New Marker of Ovarian Function

Objectives

The aim of this study was to determine day 3 Serum AMH, FSH, LH, Estradiol (E₂), Inhibin B levels, ovarian volume, and antral follicular count to assess ovarian function.

Methods

This study was conducted on 130 infertile women between age 18 and 43 years. Day 3 Serum AMH level was estimated by sandwich enzyme immunoassay; Serum FSH, S. LH, S. E₂, by solid-phase two-site chemiluminescent immunometric assay; Inhibin B by ELISA; and Ovarian volume and AFC, by transvaginal ultrasonography.

Results

With advancing age, Serum AMH level (p < 0.0001), AFC (p < 0.05), ovarian volume (>0.05), and Inhibin B (>0.05) were decreased, and Serum FSH (p < 0.05), LH (p > 0.05), and E₂ (p < 0.05) were increased. Serum AMH level was 4–6.8 ng/ml with optimal fertility in 26.15 % cases and 2.2–4.0 ng/ml with satisfactory fertility in 53.85 % cases. Serum AMH levels were more strongly correlated with AFC (p < 0.0001) and ovarian volume (p < 0.0001).

Conclusion

Serum AMH levels were more robustly correlated with AFC than FSH, LH, E₂, and Inhibin B on day 3 of the cycle. This suggested that serum AMH might be taken as single test to reflect ovarian reserve.     

Gender-, age- and time-dependent dosing of growth hormone in adults – real-world data from a decade of clinical practice in Germany

We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003–2013) from 509?GH-treated patients (mean age: 48.9?years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH dose increased more in females than males during treatment; this was statistically significant in years 2–6 (p?<?0.05). Over the 10-year study period, a time trend of an overall estimated GH dose increase by 0.06?mg/day (females) and decrease by 0.07?mg/day (males) was shown; this interaction of gender and calendar year was significant (p?<?0.0001). In both genders, overall GH dose decreased with increasing age (p?<?0.0001). Our study confirms that females and younger patients require higher GH doses compared with males and older patients.     

促性腺激素释放激素类似物抑制裸鼠卵巢癌移植瘤生长同时保护化疗后卵巢功能的研究

目的 研究促性腺激素释放激素( GnRH)类似物抑制卵巢癌裸鼠皮下移植瘤生长,同时保护化疗裸鼠卵巢功能的双重作用.方法 构建卵巢癌ES-2细胞裸鼠皮下移植瘤模型,随机分为6组(每组6只):(1)生理盐水(NS)组:皮下注射NS 0.1ml/d,1周后腹腔注射NS 0.2ml/周;(2)顺铂(DDP)组:皮下注射NS 0.1ml/d,1周后每周腹腔注射5 mg/kg DDP;(3)戈舍瑞林(goserelin)组:皮下注射goserelin 100 μg/d,1周后腹腔注射NS0.2 ml/周;(4) goserelin+ DDP组:皮下注射goserelin 100 μg/d,1周后每周腹腔注射5 mg/kg DDP;(5)西曲瑞克(cetrorelix)组:皮下注射cetrorelix 100 μg/d,1周后腹腔注射NS0.2 ml/周;(6) cetrorelix+ DDP组:皮下注射cetrorelix 100 μg/d,1周后每周腹腔注射5 mg/kg DDP.用药21 d,观察29 d.比较各组裸鼠体质量、移植瘤体积、移植瘤组织中细胞增殖相关核抗原Ki-67的阳性率、动情周期、卵巢各级卵泡比例、血清抗苗勒管激素(AMH)、卵泡刺激素(FSH)、雌二醇、孕酮水平的差异.结果 各组裸鼠体质量无明显差异(P＞0.05),用药第29天NS组为(19.8 ±2.2)g,DDP组(20.5±1.4)g,gosereline组(19.6±0.9)g,goserelin+DDP组(19.7±1.6)g,cetrorelix组(20.7±2.2)g,cetrorelix+ DDP组(19.0±1.7)g,分别比较,差异均无统计学意义(P＞0.05).用药第12天裸鼠移植瘤体积:NS组为(241±179) mm3,DDP组(78±20) mm3,gosereline组(78±55) mm3,goserelin+ DDP组(64±48) mm3,cetrorelix组(78±64) mm3,cetrorelix+ DDP组(70±19) mm3,用药组均明显小于NS组,差异有统计学意义(P＜0.05);第15、19、22、26、29天各用药组移植瘤体积也均明显小于NS组(P＜0.05).NS组Ki-67阳性率为(33± 10)％,DDP组为3.5％,goserelin组8.8％,goserelin+ DDP组1.5％,cetrorelix组(23±11)％,cetrorelix+ DDP组(8±6)％,DDP组、goserelin组和goserelin +DDP组均明显低于NS组,差异有统计学意义(P＜0.05).goserelin组原始卵泡+窦前卵泡率为(71.5±8.1)％,goserelin+DDP组为(62.4± 4.1)％,cetrorelix组(71.2±7.4)％,cetrorelix+DDP组(63.8±2.9)％,均明显高于DDP组的(47.0±4.8)％,差异均有统计学意义(P＜0.05).goserelin组血清AMH水平为(98±27) ng/ml,明显高于NS组的(66±17) ng/ml,差异有统计学意义(P＜0.05);各组裸鼠血清FSH、雌二醇和孕酮水平分别比较,差异均无统计学意义(P＞0.05).结论 GnRH类似物能抑制卵巢癌裸鼠皮下移植瘤的生长,同时上调AMH分泌、减少动情次数、延长动情周期时间、增加原始卵泡+窦前卵泡率,从而保护卵巢功能.     

Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels

ObjectiveTo evaluate the value of using both HMG and recombinant FSH (r-FSH) in the GnRH antagonist protocol for women with high AMH.Materials and methodsThis retrospective, single-center cohort study was conducted from January 2013 to December 2018. Of 277 GnRH antagonist IVF/ICSI cycles in women with anti-Mullerian hormone (AMH) ≥5 μg/L, 170 cycles receiving the combination of r-FSH and HMG (77 with HMG added at the beginning of the GnRH antagonist cycle and 93 with HMG added after GnRH antagonist administration) and 107 cycles receiving r-FSH alone were analyzed. The dynamic hormone profiles and embryonic and clinical outcomes of the patients were evaluated.ResultsWe observed significantly lower serum LH levels in the r-FSH + HMG groups during ovarian stimulation. The serum estradiol and progesterone levels were lower in the r-FSH + HMG groups on the trigger day. Nevertheless, there were no significant differences with respect to the number of oocytes retrieved, maturation, fertilization, blastocyst formation rate or ovarian hyperstimulation syndrome (OHSS). The implantation and live birth rates were increased in the r-FSH + HMG groups compared with the r-FSH alone group, with no statistical significance.ConclusionsHMG for LH supplementation in the GnRH antagonist protocol for patients with high AMH is not significantly superior to r-FSH alone in terms of ovarian response and pregnancy outcome. Nevertheless, HMG supplementation might be appropriate for women with an initially inadequate response to r-FSH or intracycle LH deficiency.     

绝经后阴道出血妇女性激素水平与子宫内膜病变关系的研究

目的　探讨绝经后阴道出血的妇女性激素变化及与子宫内膜病变的关系。方法　采用酶免疫法对 4 6例绝经后阴道出血的患者性激素水平测定。结果　绝经后阴道出血妇女血清E2 水平远高于正常绝经后妇女血清E2 值 ,两者存在显著性差异 (P <0 0 1 )。FSH、LH与正常绝经后妇女比较明显降低 (P <0 0 5 )。子宫内膜增生过长和子宫内膜癌的患者雌激素水平增高者分别占 71 4 %和 5 7 1 %。结论　绝经后阴道出血与雌激素水平增高有关